1 Anaplastic Astrocytoma Drug Market Overview 1.1 Product Overview and Scope of Anaplastic Astrocytoma Drug 1.2 Anaplastic Astrocytoma Drug Segment by Type 1.2.1 Global Anaplastic Astrocytoma Drug Sales Growth Rate Comparison by Type (2021-2027) 1.2.2 A-10 1.2.3 AS-21 1.2.4 AdRTSIL-12 1.2.5 ADU-623 1.2.6 Others 1.3 Anaplastic Astrocytoma Drug Segment by Application 1.3.1 Anaplastic Astrocytoma Drug Sales Comparison by Application: (2021-2027) 1.3.2 Hospital 1.3.3 Clinic 1.3.4 Others 1.4 Global Anaplastic Astrocytoma Drug Market Size Estimates and Forecasts 1.4.1 Global Anaplastic Astrocytoma Drug Revenue 2016-2027 1.4.2 Global Anaplastic Astrocytoma Drug Sales 2016-2027 1.4.3 Anaplastic Astrocytoma Drug Market Size by Region: 2016 Versus 2021 Versus 2027 2 Anaplastic Astrocytoma Drug Market Competition by Manufacturers 2.1 Global Anaplastic Astrocytoma Drug Sales Market Share by Manufacturers (2016-2021) 2.2 Global Anaplastic Astrocytoma Drug Revenue Market Share by Manufacturers (2016-2021) 2.3 Global Anaplastic Astrocytoma Drug Average Price by Manufacturers (2016-2021) 2.4 Manufacturers Anaplastic Astrocytoma Drug Manufacturing Sites, Area Served, Product Type 2.5 Anaplastic Astrocytoma Drug Market Competitive Situation and Trends 2.5.1 Anaplastic Astrocytoma Drug Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Anaplastic Astrocytoma Drug Players Market Share by Revenue 2.5.3 Global Anaplastic Astrocytoma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Anaplastic Astrocytoma Drug Retrospective Market Scenario by Region 3.1 Global Anaplastic Astrocytoma Drug Retrospective Market Scenario in Revenue by Region: 2016-2021 3.2 Global Anaplastic Astrocytoma Drug Retrospective Market Scenario in Sales by Region: 2016-2021 3.3 North America Anaplastic Astrocytoma Drug Market Facts & Figures by Country 3.3.1 North America Anaplastic Astrocytoma Drug Sales by Country 3.3.2 North America Anaplastic Astrocytoma Drug Revenue by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Anaplastic Astrocytoma Drug Market Facts & Figures by Country 3.4.1 Europe Anaplastic Astrocytoma Drug Sales by Country 3.4.2 Europe Anaplastic Astrocytoma Drug Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Anaplastic Astrocytoma Drug Market Facts & Figures by Region 3.5.1 Asia Pacific Anaplastic Astrocytoma Drug Sales by Region 3.5.2 Asia Pacific Anaplastic Astrocytoma Drug Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Anaplastic Astrocytoma Drug Market Facts & Figures by Country 3.6.1 Latin America Anaplastic Astrocytoma Drug Sales by Country 3.6.2 Latin America Anaplastic Astrocytoma Drug Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Anaplastic Astrocytoma Drug Market Facts & Figures by Country 3.7.1 Middle East and Africa Anaplastic Astrocytoma Drug Sales by Country 3.7.2 Middle East and Africa Anaplastic Astrocytoma Drug Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Anaplastic Astrocytoma Drug Historic Market Analysis by Type 4.1 Global Anaplastic Astrocytoma Drug Sales Market Share by Type (2016-2021) 4.2 Global Anaplastic Astrocytoma Drug Revenue Market Share by Type (2016-2021) 4.3 Global Anaplastic Astrocytoma Drug Price by Type (2016-2021) 5 Global Anaplastic Astrocytoma Drug Historic Market Analysis by Application 5.1 Global Anaplastic Astrocytoma Drug Sales Market Share by Application (2016-2021) 5.2 Global Anaplastic Astrocytoma Drug Revenue Market Share by Application (2016-2021) 5.3 Global Anaplastic Astrocytoma Drug Price by Application (2016-2021) 6 Key Companies Profiled 6.1 Advantagene Inc 6.1.1 Advantagene Inc Corporation Information 6.1.2 Advantagene Inc Description and Business Overview 6.1.3 Advantagene Inc Anaplastic Astrocytoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.1.4 Advantagene Inc Product Portfolio 6.1.5 Advantagene Inc Recent Developments/Updates 6.2 Alfa Wassermann SpA 6.2.1 Alfa Wassermann SpA Corporation Information 6.2.2 Alfa Wassermann SpA Description and Business Overview 6.2.3 Alfa Wassermann SpA Anaplastic Astrocytoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.2.4 Alfa Wassermann SpA Product Portfolio 6.2.5 Alfa Wassermann SpA Recent Developments/Updates 6.3 Amgen Inc 6.3.1 Amgen Inc Corporation Information 6.3.2 Amgen Inc Description and Business Overview 6.3.3 Amgen Inc Anaplastic Astrocytoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.3.4 Amgen Inc Product Portfolio 6.3.5 Amgen Inc Recent Developments/Updates 6.4 AngioChem Inc 6.4.1 AngioChem Inc Corporation Information 6.4.2 AngioChem Inc Description and Business Overview 6.4.3 AngioChem Inc Anaplastic Astrocytoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.4.4 AngioChem Inc Product Portfolio 6.4.5 AngioChem Inc Recent Developments/Updates 6.5 Astellas Pharma Inc. 6.5.1 Astellas Pharma Inc. Corporation Information 6.5.2 Astellas Pharma Inc. Description and Business Overview 6.5.3 Astellas Pharma Inc. Anaplastic Astrocytoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.5.4 Astellas Pharma Inc. Product Portfolio 6.5.5 Astellas Pharma Inc. Recent Developments/Updates 6.6 Bayer AG 6.6.1 Bayer AG Corporation Information 6.6.2 Bayer AG Description and Business Overview 6.6.3 Bayer AG Anaplastic Astrocytoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.6.4 Bayer AG Product Portfolio 6.6.5 Bayer AG Recent Developments/Updates 6.7 Boehringer Ingelheim GmbH 6.6.1 Boehringer Ingelheim GmbH Corporation Information 6.6.2 Boehringer Ingelheim GmbH Description and Business Overview 6.6.3 Boehringer Ingelheim GmbH Anaplastic Astrocytoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Boehringer Ingelheim GmbH Product Portfolio 6.7.5 Boehringer Ingelheim GmbH Recent Developments/Updates 6.8 Burzynski Research Institute Inc 6.8.1 Burzynski Research Institute Inc Corporation Information 6.8.2 Burzynski Research Institute Inc Description and Business Overview 6.8.3 Burzynski Research Institute Inc Anaplastic Astrocytoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.8.4 Burzynski Research Institute Inc Product Portfolio 6.8.5 Burzynski Research Institute Inc Recent Developments/Updates 6.9 Cavion LLC 6.9.1 Cavion LLC Corporation Information 6.9.2 Cavion LLC Description and Business Overview 6.9.3 Cavion LLC Anaplastic Astrocytoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.9.4 Cavion LLC Product Portfolio 6.9.5 Cavion LLC Recent Developments/Updates 6.10 Celldex Therapeutics Inc 6.10.1 Celldex Therapeutics Inc Corporation Information 6.10.2 Celldex Therapeutics Inc Description and Business Overview 6.10.3 Celldex Therapeutics Inc Anaplastic Astrocytoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.10.4 Celldex Therapeutics Inc Product Portfolio 6.10.5 Celldex Therapeutics Inc Recent Developments/Updates 6.11 Merrimack Pharmaceuticals Inc 6.11.1 Merrimack Pharmaceuticals Inc Corporation Information 6.11.2 Merrimack Pharmaceuticals Inc Anaplastic Astrocytoma Drug Description and Business Overview 6.11.3 Merrimack Pharmaceuticals Inc Anaplastic Astrocytoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.11.4 Merrimack Pharmaceuticals Inc Product Portfolio 6.11.5 Merrimack Pharmaceuticals Inc Recent Developments/Updates 6.12 Millennium Pharmaceuticals Inc 6.12.1 Millennium Pharmaceuticals Inc Corporation Information 6.12.2 Millennium Pharmaceuticals Inc Anaplastic Astrocytoma Drug Description and Business Overview 6.12.3 Millennium Pharmaceuticals Inc Anaplastic Astrocytoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.12.4 Millennium Pharmaceuticals Inc Product Portfolio 6.12.5 Millennium Pharmaceuticals Inc Recent Developments/Updates 6.13 Novartis AG 6.13.1 Novartis AG Corporation Information 6.13.2 Novartis AG Anaplastic Astrocytoma Drug Description and Business Overview 6.13.3 Novartis AG Anaplastic Astrocytoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.13.4 Novartis AG Product Portfolio 6.13.5 Novartis AG Recent Developments/Updates 6.14 Orbus Therapeutics Inc 6.14.1 Orbus Therapeutics Inc Corporation Information 6.14.2 Orbus Therapeutics Inc Anaplastic Astrocytoma Drug Description and Business Overview 6.14.3 Orbus Therapeutics Inc Anaplastic Astrocytoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.14.4 Orbus Therapeutics Inc Product Portfolio 6.14.5 Orbus Therapeutics Inc Recent Developments/Updates 6.15 Pfizer Inc 6.15.1 Pfizer Inc Corporation Information 6.15.2 Pfizer Inc Anaplastic Astrocytoma Drug Description and Business Overview 6.15.3 Pfizer Inc Anaplastic Astrocytoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.15.4 Pfizer Inc Product Portfolio 6.15.5 Pfizer Inc Recent Developments/Updates 6.16 Tocagen Inc 6.16.1 Tocagen Inc Corporation Information 6.16.2 Tocagen Inc Anaplastic Astrocytoma Drug Description and Business Overview 6.16.3 Tocagen Inc Anaplastic Astrocytoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.16.4 Tocagen Inc Product Portfolio 6.16.5 Tocagen Inc Recent Developments/Updates 6.17 Tragara Pharmaceuticals Inc 6.17.1 Tragara Pharmaceuticals Inc Corporation Information 6.17.2 Tragara Pharmaceuticals Inc Anaplastic Astrocytoma Drug Description and Business Overview 6.17.3 Tragara Pharmaceuticals Inc Anaplastic Astrocytoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.17.4 Tragara Pharmaceuticals Inc Product Portfolio 6.17.5 Tragara Pharmaceuticals Inc Recent Developments/Updates 6.18 TVAX Biomedical Inc 6.18.1 TVAX Biomedical Inc Corporation Information 6.18.2 TVAX Biomedical Inc Anaplastic Astrocytoma Drug Description and Business Overview 6.18.3 TVAX Biomedical Inc Anaplastic Astrocytoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.18.4 TVAX Biomedical Inc Product Portfolio 6.18.5 TVAX Biomedical Inc Recent Developments/Updates 6.19 ZIOPHARM Oncology Inc 6.19.1 ZIOPHARM Oncology Inc Corporation Information 6.19.2 ZIOPHARM Oncology Inc Anaplastic Astrocytoma Drug Description and Business Overview 6.19.3 ZIOPHARM Oncology Inc Anaplastic Astrocytoma Drug Sales, Revenue and Gross Margin (2016-2021) 6.19.4 ZIOPHARM Oncology Inc Product Portfolio 6.19.5 ZIOPHARM Oncology Inc Recent Developments/Updates 7 Anaplastic Astrocytoma Drug Manufacturing Cost Analysis 7.1 Anaplastic Astrocytoma Drug Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Anaplastic Astrocytoma Drug 7.4 Anaplastic Astrocytoma Drug Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Anaplastic Astrocytoma Drug Distributors List 8.3 Anaplastic Astrocytoma Drug Customers 9 Anaplastic Astrocytoma Drug Market Dynamics 9.1 Anaplastic Astrocytoma Drug Industry Trends 9.2 Anaplastic Astrocytoma Drug Growth Drivers 9.3 Anaplastic Astrocytoma Drug Market Challenges 9.4 Anaplastic Astrocytoma Drug Market Restraints 10 Global Market Forecast 10.1 Anaplastic Astrocytoma Drug Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Anaplastic Astrocytoma Drug by Type (2022-2027) 10.1.2 Global Forecasted Revenue of Anaplastic Astrocytoma Drug by Type (2022-2027) 10.2 Anaplastic Astrocytoma Drug Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Anaplastic Astrocytoma Drug by Application (2022-2027) 10.2.2 Global Forecasted Revenue of Anaplastic Astrocytoma Drug by Application (2022-2027) 10.3 Anaplastic Astrocytoma Drug Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Anaplastic Astrocytoma Drug by Region (2022-2027) 10.3.2 Global Forecasted Revenue of Anaplastic Astrocytoma Drug by Region (2022-2027) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Anaplastic Astrocytoma Drug Sales (K Pcs) Growth Rate Comparison by Type (2021-2027) Table 2. Global Anaplastic Astrocytoma Drug Sales (K Pcs) Comparison by Application (2021-2027) Table 3. Global Anaplastic Astrocytoma Drug Market Size by Region (US$ Million) (2016 VS 2021 VS 2027) Table 4. Key Manufacturers Anaplastic Astrocytoma Drug Covered in This Study Table 5. Global Anaplastic Astrocytoma Drug Sales (K Pcs) of Key Manufacturers (2016-2021) Table 6. Global Anaplastic Astrocytoma Drug Sales Share by Manufacturers (2016-2021) Table 7. Global Anaplastic Astrocytoma Drug Revenue (US$ Million) by Manufacturers (2016-2021) Table 8. Global Anaplastic Astrocytoma Drug Revenue Share by Manufacturers (2016-2021) Table 9. Global Market Anaplastic Astrocytoma Drug Average Price (USD/Pcs) of Key Manufacturers (2016-2021) Table 10. Manufacturers Anaplastic Astrocytoma Drug Manufacturing Sites and Area Served Table 11. Manufacturers Anaplastic Astrocytoma Drug Product Type Table 12. Global Anaplastic Astrocytoma Drug Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Anaplastic Astrocytoma Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anaplastic Astrocytoma Drug as of 2020) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Anaplastic Astrocytoma Drug Sales by Region (2016-2021) & (K Pcs) Table 16. Global Anaplastic Astrocytoma Drug Sales Market Share by Region (2016-2021) Table 17. Global Anaplastic Astrocytoma Drug Revenue by Region (2016-2021) & (US$ Million) Table 18. North America Anaplastic Astrocytoma Drug Sales by Country (2016-2021) & (K Pcs) Table 19. North America Anaplastic Astrocytoma Drug Sales Market Share by Country (2016-2021) Table 20. North America Anaplastic Astrocytoma Drug Revenue by Country (2016-2021) & (US$ Million) Table 21. North America Anaplastic Astrocytoma Drug Revenue Market Share by Country (2016-2021) Table 22. Europe Anaplastic Astrocytoma Drug Sales by Country (2016-2021) & (K Pcs) Table 23. Europe Anaplastic Astrocytoma Drug Sales Market Share by Country (2016-2021) Table 24. Europe Anaplastic Astrocytoma Drug Revenue by Country (2016-2021) & (US$ Million) Table 25. Europe Anaplastic Astrocytoma Drug Revenue Market Share by Country (2016-2021) Table 26. Asia Pacific Anaplastic Astrocytoma Drug Sales by Region (2016-2021) & (K Pcs) Table 27. Asia Pacific Anaplastic Astrocytoma Drug Sales Market Share by Region (2016-2021) Table 28. Asia Pacific Anaplastic Astrocytoma Drug Revenue by Region (2016-2021) & (US$ Million) Table 29. Asia Pacific Anaplastic Astrocytoma Drug Revenue Market Share by Region (2016-2021) Table 30. Latin America Anaplastic Astrocytoma Drug Sales by Country (2016-2021) & (K Pcs) Table 31. Latin America Anaplastic Astrocytoma Drug Sales Market Share by Country (2016-2021) Table 32. Latin America Anaplastic Astrocytoma Drug Revenue by Country (2016-2021) & (US$ Million) Table 33. Latin America Anaplastic Astrocytoma Drug Revenue Market Share by Country (2016-2021) Table 34. Middle East and Africa Anaplastic Astrocytoma Drug Sales by Country (2016-2021) & (K Pcs) Table 35. Middle East and Africa Anaplastic Astrocytoma Drug Sales Market Share by Country (2016-2021) Table 36. Middle East and Africa Anaplastic Astrocytoma Drug Revenue by Country (2016-2021) & (US$ Million) Table 37. Middle East and Africa Anaplastic Astrocytoma Drug Revenue Market Share by Country (2016-2021) Table 38. Global Anaplastic Astrocytoma Drug Sales (K Pcs) by Type (2016-2021) Table 39. Global Anaplastic Astrocytoma Drug Sales Market Share by Type (2016-2021) Table 40. Global Anaplastic Astrocytoma Drug Revenue (Million US$) by Type (2016-2021) Table 41. Global Anaplastic Astrocytoma Drug Revenue Share by Type (2016-2021) Table 42. Global Anaplastic Astrocytoma Drug Price (USD/Pcs) by Type (2016-2021) Table 43. Global Anaplastic Astrocytoma Drug Sales (K Pcs) by Application (2016-2021) Table 44. Global Anaplastic Astrocytoma Drug Sales Market Share by Application (2016-2021) Table 45. Global Anaplastic Astrocytoma Drug Revenue (Million US$) by Application (2016-2021) Table 46. Global Anaplastic Astrocytoma Drug Revenue Share by Application (2016-2021) Table 47. Global Anaplastic Astrocytoma Drug Price (USD/Pcs) by Application (2016-2021) Table 48. Advantagene Inc Corporation Information Table 49. Advantagene Inc Description and Business Overview Table 50. Advantagene Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 51. Advantagene Inc Anaplastic Astrocytoma Drug Product Table 52. Advantagene Inc Recent Developments/Updates Table 53. Alfa Wassermann SpA Corporation Information Table 54. Alfa Wassermann SpA Description and Business Overview Table 55. Alfa Wassermann SpA Anaplastic Astrocytoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 56. Alfa Wassermann SpA Anaplastic Astrocytoma Drug Product Table 57. Alfa Wassermann SpA Recent Developments/Updates Table 58. Amgen Inc Corporation Information Table 59. Amgen Inc Description and Business Overview Table 60. Amgen Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 61. Amgen Inc Anaplastic Astrocytoma Drug Product Table 62. Amgen Inc Recent Developments/Updates Table 63. AngioChem Inc Corporation Information Table 64. AngioChem Inc Description and Business Overview Table 65. AngioChem Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 66. AngioChem Inc Anaplastic Astrocytoma Drug Product Table 67. AngioChem Inc Recent Developments/Updates Table 68. Astellas Pharma Inc. Corporation Information Table 69. Astellas Pharma Inc. Description and Business Overview Table 70. Astellas Pharma Inc. Anaplastic Astrocytoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 71. Astellas Pharma Inc. Anaplastic Astrocytoma Drug Product Table 72. Astellas Pharma Inc. Recent Developments/Updates Table 73. Bayer AG Corporation Information Table 74. Bayer AG Description and Business Overview Table 75. Bayer AG Anaplastic Astrocytoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 76. Bayer AG Anaplastic Astrocytoma Drug Product Table 77. Bayer AG Recent Developments/Updates Table 78. Boehringer Ingelheim GmbH Corporation Information Table 79. Boehringer Ingelheim GmbH Description and Business Overview Table 80. Boehringer Ingelheim GmbH Anaplastic Astrocytoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 81. Boehringer Ingelheim GmbH Anaplastic Astrocytoma Drug Product Table 82. Boehringer Ingelheim GmbH Recent Developments/Updates Table 83. Burzynski Research Institute Inc Corporation Information Table 84. Burzynski Research Institute Inc Description and Business Overview Table 85. Burzynski Research Institute Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 86. Burzynski Research Institute Inc Anaplastic Astrocytoma Drug Product Table 87. Burzynski Research Institute Inc Recent Developments/Updates Table 88. Cavion LLC Corporation Information Table 89. Cavion LLC Description and Business Overview Table 90. Cavion LLC Anaplastic Astrocytoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 91. Cavion LLC Anaplastic Astrocytoma Drug Product Table 92. Cavion LLC Recent Developments/Updates Table 93. Celldex Therapeutics Inc Corporation Information Table 94. Celldex Therapeutics Inc Description and Business Overview Table 95. Celldex Therapeutics Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 96. Celldex Therapeutics Inc Anaplastic Astrocytoma Drug Product Table 97. Celldex Therapeutics Inc Recent Developments/Updates Table 98. Merrimack Pharmaceuticals Inc Corporation Information Table 99. Merrimack Pharmaceuticals Inc Description and Business Overview Table 100. Merrimack Pharmaceuticals Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 101. Merrimack Pharmaceuticals Inc Anaplastic Astrocytoma Drug Product Table 102. Merrimack Pharmaceuticals Inc Recent Developments/Updates Table 103. Millennium Pharmaceuticals Inc Corporation Information Table 104. Millennium Pharmaceuticals Inc Description and Business Overview Table 105. Millennium Pharmaceuticals Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 106. Millennium Pharmaceuticals Inc Anaplastic Astrocytoma Drug Product Table 107. Millennium Pharmaceuticals Inc Recent Developments/Updates Table 108. Novartis AG Corporation Information Table 109. Novartis AG Description and Business Overview Table 110. Novartis AG Anaplastic Astrocytoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 111. Novartis AG Anaplastic Astrocytoma Drug Product Table 112. Novartis AG Recent Developments/Updates Table 113. Orbus Therapeutics Inc Corporation Information Table 114. Orbus Therapeutics Inc Description and Business Overview Table 115. Orbus Therapeutics Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 116. Orbus Therapeutics Inc Anaplastic Astrocytoma Drug Product Table 117. Orbus Therapeutics Inc Recent Developments/Updates Table 118. Pfizer Inc Corporation Information Table 119. Pfizer Inc Description and Business Overview Table 120. Pfizer Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 121. Pfizer Inc Anaplastic Astrocytoma Drug Product Table 122. Pfizer Inc Recent Developments/Updates Table 123. Tocagen Inc Corporation Information Table 124. Tocagen Inc Description and Business Overview Table 125. Tocagen Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 126. Tocagen Inc Anaplastic Astrocytoma Drug Product Table 127. Tocagen Inc Recent Developments/Updates Table 128. Tragara Pharmaceuticals Inc Corporation Information Table 129. Tragara Pharmaceuticals Inc Description and Business Overview Table 130. Tragara Pharmaceuticals Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 131. Tragara Pharmaceuticals Inc Anaplastic Astrocytoma Drug Product Table 132. Tragara Pharmaceuticals Inc Recent Developments/Updates Table 133. TVAX Biomedical Inc Corporation Information Table 134. TVAX Biomedical Inc Description and Business Overview Table 135. TVAX Biomedical Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 136. TVAX Biomedical Inc Anaplastic Astrocytoma Drug Product Table 137. TVAX Biomedical Inc Recent Developments/Updates Table 138. ZIOPHARM Oncology Inc Corporation Information Table 139. ZIOPHARM Oncology Inc Description and Business Overview Table 140. ZIOPHARM Oncology Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2016-2021) Table 141. ZIOPHARM Oncology Inc Anaplastic Astrocytoma Drug Product Table 142. ZIOPHARM Oncology Inc Recent Developments/Updates Table 143. Production Base and Market Concentration Rate of Raw Material Table 144. Key Suppliers of Raw Materials Table 145. Anaplastic Astrocytoma Drug Distributors List Table 146. Anaplastic Astrocytoma Drug Customers List Table 147. Anaplastic Astrocytoma Drug Market Trends Table 148. Anaplastic Astrocytoma Drug Growth Drivers Table 149. Anaplastic Astrocytoma Drug Market Restraints Table 150. Global Anaplastic Astrocytoma Drug Sales Forecast by Type (2022-2027) & (K Pcs) Table 151. Global Anaplastic Astrocytoma Drug Sales Market Share Forecast by Type (2022-2027) Table 152. Global Anaplastic Astrocytoma Drug Revenue Forecast by Type (2022-2027) & (US$ Million) Table 153. Global Anaplastic Astrocytoma Drug Revenue Market Share Forecast by Type (2022-2027) Table 154. Global Anaplastic Astrocytoma Drug Sales Forecast by Application (2022-2027) & (K Pcs) Table 155. Global Anaplastic Astrocytoma Drug Sales Market Share Forecast by Application (2022-2027) Table 156. Global Anaplastic Astrocytoma Drug Revenue Forecast by Application (2022-2027) & (US$ Million) Table 157. Global Anaplastic Astrocytoma Drug Revenue Market Share Forecast by Application (2022-2027) Table 158. Global Anaplastic Astrocytoma Drug Sales Forecast by Region (2022-2027) & (K Pcs) Table 159. Global Anaplastic Astrocytoma Drug Sales Market Share Forecast by Region (2022-2027) Table 160. Global Anaplastic Astrocytoma Drug Revenue Forecast by Region (2022-2027) & (US$ Million) Table 161. Global Anaplastic Astrocytoma Drug Revenue Market Share Forecast by Region (2022-2027) Table 162. Research Programs/Design for This Report Table 163. Key Data Information from Secondary Sources Table 164. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Anaplastic Astrocytoma Drug Figure 2. Global Anaplastic Astrocytoma Drug Market Share by Type in 2020 & 2027 Figure 3. A-10 Product Picture Figure 4. AS-21 Product Picture Figure 5. AdRTSIL-12 Product Picture Figure 6. ADU-623 Product Picture Figure 7. Others Product Picture Figure 8. Global Anaplastic Astrocytoma Drug Market Share by Application in 2020 & 2027 Figure 9. Hospital Figure 10. Clinic Figure 11. Others Figure 12. Global Anaplastic Astrocytoma Drug Revenue, (US$ Million), 2016 VS 2021 VS 2027 Figure 13. Global Anaplastic Astrocytoma Drug Market Size 2016-2027 (US$ Million) Figure 14. Global Anaplastic Astrocytoma Drug Sales 2016-2027 (K Pcs) Figure 15. Global Anaplastic Astrocytoma Drug Market Size Market Share by Region: 2016 VS 20210 VS 2027 Figure 16. Anaplastic Astrocytoma Drug Sales Share by Manufacturers in 2020 Figure 17. Global Anaplastic Astrocytoma Drug Revenue Share by Manufacturers in 2020 Figure 18. The Global 5 and 10 Largest Anaplastic Astrocytoma Drug Players: Market Share by Revenue in 2020 Figure 19. Anaplastic Astrocytoma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021 Figure 20. Global Anaplastic Astrocytoma Drug Sales Market Share by Region (2016-2021) Figure 21. Global Anaplastic Astrocytoma Drug Sales Market Share by Region in 2020 Figure 22. Global Anaplastic Astrocytoma Drug Revenue Market Share by Region (2016-2021) Figure 23. Global Anaplastic Astrocytoma Drug Revenue Market Share by Region in 2020 Figure 24. U.S. Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 25. Canada Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 26. Germany Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 27. France Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 28. U.K. Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 29. Italy Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 30. Russia Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 31. China Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 32. Japan Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 33. South Korea Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 34. India Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 35. Australia Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 36. Taiwan Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 37. Indonesia Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 38. Thailand Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 39. Malaysia Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 40. Philippines Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 41. Vietnam Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 42. Mexico Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 43. Brazil Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 44. Argentina Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 45. Turkey Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 46. Saudi Arabia Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 47. U.A.E Anaplastic Astrocytoma Drug Revenue Growth Rate (2016-2021) (US$ Million) Figure 48. Sales Market Share of Anaplastic Astrocytoma Drug by Type (2016-2021) Figure 49. Sales Market Share of Anaplastic Astrocytoma Drug by Application (2016-2021) Figure 50. Sales Market Share of Anaplastic Astrocytoma Drug by Application in 2020 Figure 51. Revenue Share of Anaplastic Astrocytoma Drug by Application (2016-2021) Figure 52. Revenue Share of Anaplastic Astrocytoma Drug by Application in 2020 Figure 53. Manufacturing Cost Structure of Anaplastic Astrocytoma Drug Figure 54. Manufacturing Process Analysis of Anaplastic Astrocytoma Drug Figure 55. Anaplastic Astrocytoma Drug Industrial Chain Analysis Figure 56. Channels of Distribution Figure 57. Distributors Profiles Figure 58. Bottom-up and Top-down Approaches for This Report Figure 59. Data Triangulation Figure 60. Key Executives Interviewed

Advantagene Inc Alfa Wassermann SpA Amgen Inc AngioChem Inc Astellas Pharma Inc. Bayer AG Boehringer Ingelheim GmbH Burzynski Research Institute Inc Cavion LLC Celldex Therapeutics Inc Merrimack Pharmaceuticals Inc Millennium Pharmaceuticals Inc Novartis AG Orbus Therapeutics Inc Pfizer Inc Tocagen Inc Tragara Pharmaceuticals Inc TVAX Biomedical Inc ZIOPHARM Oncology Inc